Mirdametinib (PD0325901)

For research use only. Not for use in humans.

Pfizer辉瑞授权 目录号:S1036

Mirdametinib (PD0325901) Chemical Structure

CAS No. 391210-10-9

Mirdametinib (PD0325901) 是一种选择性的,非ATP竞争性MEK抑制剂,无细胞试验中IC50为0.33 nM,对ERK1和ERK2磷酸化抑制作用比CI-1040强500倍左右。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1149.21 现货
RMB 580.85 现货
RMB 2226.87 现货
RMB 6305.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Mirdametinib (PD0325901)发表文献525篇:

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述 Mirdametinib (PD0325901) 是一种选择性的,非ATP竞争性MEK抑制剂,无细胞试验中IC50为0.33 nM,对ERK1和ERK2磷酸化抑制作用比CI-1040强500倍左右。Phase 2。
靶点
MEK [1]
(Cell-free assay)
0.33 nM
体外研究

PD0325901比另一种MEK抑制剂CI-1040具有更高的渗透率。与CI-1040相比,PD 0325901可以到达体系的更深层。[1]PD0325901是非ATP竞争性的MAPK激酶MEK抑制剂,抑制鼠类结肠26细胞的MEK时IC50为0.33nM。苏氨酸/酪氨酸激酶MEK是RAS/RAF/MEK/ERK信号通路的关键组成部分,在人类肿瘤细胞中通常是激活的。PD0325901精确有效地抑制MEK,作用于MEK1和MEK2时Ki值为1nM。PD0325901作用于细胞ERK1和ERK2的磷酸化效果比CI-1040强到大约500倍。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell MkS1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzPyCwTT6= MWPTRW5ITVJ?
human M14 cell NH;ZRplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fxXWlvcGmkaYTpc44hd2ZiaIXtZY4hVTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OUBvVS5? MmHNV2FPT0WU
human SK-MEL-28 cell NIW5VJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLBcZZKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNUKgcm0v MV3TRW5ITVJ?
human NOMO-1 cell NVi5V2tCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWrlOHFUUW6qaXLpeIlwdiCxZjDoeY1idiCQT13PMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB5IH7NMi=> MUjTRW5ITVJ?
human A375 cell Mm\TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLXdW1KdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlY6KG6PLh?= MVjTRW5ITVJ?
human DU-4475 cell M2r2cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PRR2lvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPTdibl2u NGfvNGpUSU6JRWK=
human C32 cell M2D0VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33nV2lvcGmkaYTpc44hd2ZiaIXtZY4hSzN{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62O{BvVS5? M3\5c3NCVkeHUh?=
human BPH-1 cell Mn\uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fnSWlvcGmkaYTpc44hd2ZiaIXtZY4hSlCKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk2KG6PLh?= NVXjbo5xW0GQR1XS
human CP50-MEL-B cell NWSz[HlFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XPbGlvcGmkaYTpc44hd2ZiaIXtZY4hS1B3MD3NSWwuSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNUigcm0v NXfzZZJKW0GQR1XS
human H9 cell NUfHZo04T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4K4e2lvcGmkaYTpc44hd2ZiaIXtZY4hUDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke3JI5ONg>? M1LXPHNCVkeHUh?=
human HTC-C3 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGhVSy2FMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPFkhdk1w NGnQcXlUSU6JRWK=
human BHT-101 cell NUKwRZdWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlchdk1w NWXxZoFDW0GQR1XS
human COLO-741 cell M1n3[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4exUGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjFibl2u MkTNV2FPT0WU
human OVCAR-5 cell NH7UU4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn:xTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45OiCwTT6= NV7VXYQzW0GQR1XS
human A549 cell NUjLRmlPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2PKOWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFkhdk1w NFfPNYVUSU6JRWK=
human SH-4 cell growth NF;tb4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DxPGlvcGmkaYTpc44hd2ZiaIXtZY4hW0hvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNlYhdk1w M3Xp[HNCVkeHUh?=
human SK-N-AS cell NY[yOFI6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUPtTWVCUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWFUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC52NDDuUU4> MV3TRW5ITVJ?
human HT-144 cell MkG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXSwXYtXUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xOFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Njl5IH7NMi=> Mo\aV2FPT0WU
human MEL-HO cell M2fsT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFvvfpdKdmirYnn0bY9vKG:oIHj1cYFvKE2HTD3IU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2u M4iyc3NCVkeHUh?=
human COLO-679 cell M4L1XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{TYS2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yMTDuUS=> MV3TRW5ITVJ?
human HuP-T4 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHG3[GtKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjl6IH7NMi=> M1TmdnNCVkeHUh?=
human H-EMC-SS cell M1nPNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXrTXVdMUW6qaXLpeIlwdiCxZjDoeY1idiCKLVXNR{1UWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkCyJI5ONg>? NUf3enBbW0GQR1XS
human LB2518-MEL cell NU\hNGdjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOjVzOD3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5zMzDuUU4> NGfHfIVUSU6JRWK=
human HL-60 cell NYfLV|VNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfmemN{UW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjF3IH7NMi=> M3rwR3NCVkeHUh?=
human NCI-H1666 cell NIPGfGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4noOGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFwMUegcm0v MnTPV2FPT0WU
human A101D cell NXjRdJFxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWjWZpVbUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=> MYPTRW5ITVJ?
human RVH-421 cell NUXmPFN4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoriTY5pcWKrdHnvckBw\iCqdX3hckBTXkhvNEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVIvPjRibl2u NIjTO3FUSU6JRWK=
human Hs-578-T cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmr5TY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjd7IH7NMi=> NFWyOFVUSU6JRWK=
human A375 cells NEfQVG9Rem:uaX\ldoF1cW:wIHHzd4F6 M{XVW|czKGh? NHK3[mhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOg[ZhxemW|c3nu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdCC2aYTldk1odG9iYYPzZZktKEmFNUC9NVMhdk1w MV6yN|Q4PDN6OB?=
human DOK cell NF;BSplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGRQUyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF|LkSgcm0v NHryVXFUSU6JRWK=
human Mewo cell Mk\6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX3hO4NLUW6qaXLpeIlwdiCxZjDoeY1idiCPZYfvJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPDVibl2u NWTXXlE1W0GQR1XS
human ONS-76 cell NYOzR4JmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXO4Z4xCUW6qaXLpeIlwdiCxZjDoeY1idiCRTmOtO|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC53MTDuUU4> NX6xXHF5W0GQR1XS
human UACC-257 cell MoXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjJibl2u MnLRV2FPT0WU
human SW626 cell NHT5OndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2\0[WlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4Mk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46OSCwTT6= MWPTRW5ITVJ?
human SW620 cell NVqwOnk5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{juWmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46PSCwTT6= NIrleI1USU6JRWK=
human TYK-nu cell M4H1[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUGxd5pTUW6qaXLpeIlwdiCxZjDoeY1idiCWWVutcpUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS5zMzDuUU4> Mkf4V2FPT0WU
human ACN cell NF3t[IxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1W0fWlvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuO|Yhdk1w MV\TRW5ITVJ?
human MIAPaCa2 cells NFjjOmxRem:uaX\ldoF1cW:wIHHzd4F6 M4ridWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMtKEmFNUC9NVchdk1w MoTyNlM1PzR|OEi=
human T-24 cell Mnf2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLUZ29KdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU44OSCwTT6= NXXOUWhYW0GQR1XS
human AGS cell M4DxZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{DTb2lvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuOFEhdk1w NVO4XWxzW0GQR1XS
human SW872 cell MkjKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVzjVWl3UW6qaXLpeIlwdiCxZjDoeY1idiCVV{i3NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI4Njl7IH7NMi=> MVTTRW5ITVJ?
human C2BBe1 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWHINI5vUW6qaXLpeIlwdiCxZjDoeY1idiCFMlLC[VEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQC53NDDuUU4> M3\aTXNCVkeHUh?=
human MZ7-mel cell MoPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzMeo1oUW6qaXLpeIlwdiCxZjDoeY1idiCPWketcYVtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjlwNEOgcm0v MljaV2FPT0WU
human HCC2998 cell MkfZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{43PiCwTT6= M2PFc3NCVkeHUh?=
human HO-1-N-1 cell MkPrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4r5d2lvcGmkaYTpc44hd2ZiaIXtZY4hUE9vMT3OMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC52MzDuUU4> MmjuV2FPT0WU
human SW756 cell Ml;XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzzXmR6UW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR3IH7NMi=> MmDhV2FPT0WU
human NCI-H1437 cell M1ztUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUSzO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR7IH7NMi=> NVHrXG96W0GQR1XS
human NCI-H747 cell NIHNTpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{O3cmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3OFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC57ODDuUU4> M3LsSHNCVkeHUh?=
human SK-MEL-2 cell M{nqe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYXIdmpiUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN3LkKgcm0v NEC3SW5USU6JRWK=
human MZ2-MEL cell M2XZ[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4fWW2lvcGmkaYTpc44hd2ZiaIXtZY4hVVp{LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM2NjZ3IH7NMi=> M4q0S3NCVkeHUh?=
human PSN1 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVTJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|OD60OUBvVQ>? NWDRdFlJW0GQR1XS
human CAL-39 cell Mnq3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjPNGpKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjB2IH7NMi=> Mn\lV2FPT0WU
human LOXIMVI cell NVHOW2wyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEDFWJFKdmirYnn0bY9vKG:oIHj1cYFvKEyRWFnNWmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{QS5|OTDuUU4> NGK5cmNUSU6JRWK=
human COLO-792 cell NUDCbpY{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrSdWNKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDNwMUWgcm0v NFPyO29USU6JRWK=
human CAL-27 cell NVvMNYxQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M32xUWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFQvQTFibl2= MUjTRW5ITVJ?
human AsPC-1 cell NXrleoN4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MULJcohq[mm2aX;uJI9nKGi3bXHuJGF{WENvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1MlI5KG6PLh?= MnTxV2FPT0WU
human NCI-H2291 cell M3L1bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIL3Z2xKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlI6OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR4LkS2JI5ONg>? M{j3cXNCVkeHUh?=
human RCM-1 cell MnnTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLzfG5QUW6qaXLpeIlwdiCxZjDoeY1idiCUQ12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ3Njh3IH7NMi=> MULTRW5ITVJ?
human NCI-H292 cell NYXsd5RVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoDpTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ4NjN7IH7NMi=> NWDH[W9EW0GQR1XS
human WM-115 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlT0TY5pcWKrdHnvckBw\iCqdX3hckBYVS1zMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20PE42KG6PLh?= M4rVOXNCVkeHUh?=
human RT-112 cell NHfyOIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M121XGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFgvQDRibl2u NV22U3Z[W0GQR1XS
human HT-29 cell MlrpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUXGUJBjUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUxNjR7IH7NMi=> NFnKbZpUSU6JRWK=
human RKO cell growth MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4\pUWlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFIhdk1w NWLmVXlwW0GQR1XS
human KY821 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnEZYtKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVMvOyCwTT6= NWrTRmdHW0GQR1XS
human LB1047-RCC cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3zMVmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTV7Lk[1JI5ONg>? MUnTRW5ITVJ?
human SW1116 cell NEPZflVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TEUGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlAvPDlibl2u MmHnV2FPT0WU
human P12-ICHIKAWA cell NFvTZpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJHAyOi2LQ1jJT2FYSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ{LkK3JI5ONg>? MX\TRW5ITVJ?
human HCC70 cell Mli4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moj2TY5pcWKrdHnvckBw\iCqdX3hckBJS0N5MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[zMlAyKG6PLh?= M2Lx[3NCVkeHUh?=
human MIA-PaCa-2 cell NETpeY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mkf1TY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjNwNUOgcm0v NX\idlFKW0GQR1XS
human LoVo cell NGHVS3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14NT6yPUBvVS5? Mm\EV2FPT0WU
human LB2241-RCC cell NHvEW2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\wbYtKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14NT61NkBvVS5? MUPTRW5ITVJ?
human GAK cell NIG2eW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NW\YcHFYUW6qaXLpeIlwdiCxZjDoeY1idiCJQVugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Ok45PyCwTT6= MWnTRW5ITVJ?
human RD cell M33CN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkjRTY5pcWKrdHnvckBw\iCqdX3hckBTTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ5LkGgcm0v MYjTRW5ITVJ?
human KNS-62 cell NXn1V|lwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NID3PYZKdmirYnn0bY9vKG:oIHj1cYFvKEuQUz22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY6Njl7IH7NMi=> NXG5U|B4W0GQR1XS
human HD-MY-Z cell NX:1VFd6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWKwTYV6UW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PzFwMUKgcm0v M2TJV3NCVkeHUh?=
human COR-L105 cell NUDxTYhIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvPzFibl2u MnvQV2FPT0WU
human IA-LM cell NHq0TnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJGlCNUyPIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;N{OuNlghdk1w NVPvOlRSW0GQR1XS
human EM-2 cell Mo\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2rYO2lvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe0Mlchdk1w M2PEZnNCVkeHUh?=
human NB69 cell M4faTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PUcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5 NG\V[2hUSU6JRWK=
human HuP-T3 cell NFj0cHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUizMlk{KG6PLh?= NG\Qc3RUSU6JRWK=
human BB30-HNC cell M3uwfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7mVpNKdmirYnn0bY9vKG:oIHj1cYFvKEKEM{CtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QDVwNUGgcm0v MonMV2FPT0WU
human HT-1080 cell MoDaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\0UFVKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05PS56ODDuUU4> MU\TRW5ITVJ?
human RMG-I cell M1zxPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXLWNIp2UW6qaXLpeIlwdiCxZjDoeY1idiCUTVetTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjN2IH7NMi=> M1XxRXNCVkeHUh?=
human HCC1419 cell NFfYfpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYPoZ25bUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxOFE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTFwM{igcm0v NYfhfVJQW0GQR1XS
human SW780 cell NXy3fGVDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NITEdmVKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVIvOzJibl2u MYHTRW5ITVJ?
human SNU-387 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;4TY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVMvOzZibl2= M{PaR3NCVkeHUh?=
human LAMA-84 cell MkTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{f1eGlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1NjZ6IH7NMi=> NYXZUINVW0GQR1XS
human MV-4-11 cell M3vteWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fmb2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1Njd|IH7NMi=> NXvNcY85W0GQR1XS
human EGI-1 cell M3rrOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmGyTY5pcWKrdHnvckBw\iCqdX3hckBGT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm1MlgyKG6PLh?= MVnTRW5ITVJ?
human NCI-SNU-1 cell Mn2yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkXITY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06Pi55MzDuUU4> M4rKN3NCVkeHUh?=
human MEG-01 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUfYbpNtUW6qaXLpeIlwdiCxZjDoeY1idiCPRVetNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06Py55NzDuUU4> NInKR45USU6JRWK=
human OMC-1 cell MlPTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2GzbmlvcGmkaYTpc44hd2ZiaIXtZY4hV02FLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvOjNibl2u M3HIWXNCVkeHUh?=
human NB10 cell NETBO2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkjxTY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCwMlQzKG6PLh?= NX7yWXpvW0GQR1XS
human CAL-62 cell MkXUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLFTVVKdmirYnn0bY9vKG:oIHj1cYFvKEODTD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOC55ODDuUU4> M1\lfXNCVkeHUh?=
human NCI-H2087 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEf1cVNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyMT6xOEBvVS5? MULTRW5ITVJ?
human MDA-MB-175-VII cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFK4XpZKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPzVvVlnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZk> NX\iR5p3W0GQR1XS
human LS-513 cell NEX1VI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2P4UWlvcGmkaYTpc44hd2ZiaIXtZY4hVFNvNUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVE1Njh|IH7NMi=> NVXnfIc{W0GQR1XS
human HN cell growth NIjGRXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\GcWlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMkKuOVkhdk1w NXLXdW94W0GQR1XS
human ABC-1 cell Mme5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFL2bY5KdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVI{NjB{IH7NMi=> NWjRTFZtW0GQR1XS
human SJSA-1 cell NIfjb5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNLW0FvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGyN{4yQSCwTT6= MUHTRW5ITVJ?
human PANC1 cells M1;mNGZ2dmO2aX;uJIF{e2G7 MorqNVAh|ryP NXfpc3M4OSCq M{jURWlvcGmkaYTpc44hd2ZiTVXLNUBqdiCqdX3hckBRSU6FMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heEW{a{GvNkBt\X[nbDDheEAyOCC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> NFu1TIszPTd4Nk[zNy=>
human MCF7 cells MWXGeY5kfGmxbjDhd5NigQ>? Mnj4O|UhdWmwcx?= MV3Jcohq[mm2aX;uJI9nKE2Ha{GvNkBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGVTUyCyaH;zdIhwenmuYYTpc44h[W[2ZYKgO|UhdWmwczDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz MWGyN|M6QDR3Mx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / p-AKT / Cyclin D1 / p27; 

PubMed: 22573716     


parental or MEK inhibitor-resistant clonal populations (1182, 1183, and 1187) were treated with increasing doses of PD0325901 for 24 hours and subjected to immunoblot analysis using the indicated antibodies.

p-p70S6K(T389) / p4EBP1(S65) / pS6(S235); 

PubMed: 27699948     


Sensitive (MKN-45, OKAJIMA, HSC-57, GUS, NUGC-4, OCUM-1, SNU-719, and IM95) and resistant (SH-10-TC, MKN-1, HSC-39, NCI-N87, H-111-TC, KE-97, SNU-484, and TMK-1) cell lines were treated with DMSO or PD0325901 (0.1 or 1 μM) for 24 h and then subjected to Western blotting using antibodies against pERK, pAKT, p-p70S6K, p4EBP1, pS6, and GAPDH.

cleaved PARP; 

PubMed: 22573716     


NF1-deficient U251 or LN229 GBM cells were treated with PD0325901 for 4 days and subjected to immunoblot analysis using the indicated antibodies.

DR5; 

PubMed: 25867065     


The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h.

22573716 27699948 25867065
Immunofluorescence
Fibronectin / Actin / pFAK; 

PubMed: 28187762     


Representative immunofluorescence images of FNMA by GBM-3 cells treated either with DMSO (b) or PD0325901 (c). Fibronectin is depicted in green and DAPI (blue) was used as counterstain. PD0325901 did not appear to induce FNMA by GBM-3 cells. Rhodamine-phalloidin staining of actin in DMSO-treated (d) or PD0325901-treated GBM-3 cells (e). Note significant cell shape change and actin fiber organization. Scale bar in (e) is 5 μm. Triple stain for actin (red), p-FAK (green) and DAPI (blue) in DMSO-treated (f) and PD0325901-treated (g) GBM-3 cells. PD0325901 appears to induce the localization of p-FAK at sites of cell-ECM attachment. Thirty-micron thick z-stack of DMSO (h) and PD0325901-treated (i) collected by confocal microscopy of multicellular aggregates of GBM-3. Note marked change in actin organization from cortical to stress fibers. Scale bar in (i) is 30 μm.

ZO-1; 

PubMed: 25394671     


16HBE cells were fixed and stained for ZO-1 and DNA. Scale bar, 20 μm.

28187762 25394671
体内研究 PD0325901阻止细胞黑色素瘤细胞系的生长,使异种移植鼠模型的细胞周期停止在G1期,引起细胞凋亡单独口服25 mg/kg PD032590124后,ERK的磷酸化作用被阻断达到50%以上。PD 0325901的抗癌活性已经被用于更广泛的人类移植瘤的研究中,在研究的人类肿瘤模型中,有6/7被PD 0325901明显抑制。[2] PD0325901抑制恶性黑色素瘤细胞系生长。PD0325901抑制TPC-1细胞和K2细胞生长,GI50分别为11和6.3 nM。PD0325901浓度非常低时(10 nM)也明显抑制携带BRAF突变的PTC细胞生长,且同样浓度时只稍微提高携带RET/PTC1重排的PTC细胞生长。PD0325901作用于多种PTC细胞系,有效抑制ERK1/2磷酸化。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

体外级联实验:

在有含p44MAPK(GST-MAPK)的谷胱甘肽S-转移酶融合蛋白和含p45MEK(GST-MEK)的谷胱甘肽S-转移酶融合蛋白存在情况下,测定32P渗透到髓鞘碱性蛋白(MBP)的渗透率。实验溶液包括20 mM HEPES,pH 为7.4,10 mM MgCl2,1 mM MnCl2,1 mM EGTA,50 mM [gamma-32P]ATP,10 mg GST-MEK,0.5 mg GST-MAPK,和40 mg MBP,终体积为100 mL。实验进行20分钟后,加入三氯乙酸终止反应,然后通过GF/C过滤器过滤。使用1205 Beta板测定保留在过滤器中的32P。测定不同剂量PD0325901,绘制剂量反应曲线。
细胞实验:

[3]

- 合并
  • Cell lines: PTC细胞
  • Concentrations: 0.1 nM- 1 μM
  • Incubation Time: 48小时
  • Method:

    1×104个PTC细胞接种在含1mL培养基的24孔板上,在37oC下温育4天。在实验第一天加入不同浓度MEK抑制剂,重复三次。MTT溶于0.8% NaCl溶液,浓度为5 mg/mL,实验第三天,每孔加入0.2 mL,测定GI50或者测定每天的细胞生长曲线。细胞和MTT在37oC下温育3小时。然后从孔中吸出液体除去。染色的细胞溶于0.5 mL DMSO,然后使用Synergy HT增殖酶标仪在570 nm处测定吸光值。然后测定GI50, 按公式 100×(T − T0)/(C − T0)计算细胞生长。


    (Only for Reference)
动物实验:

[3]

- 合并
  • Animal Models: 携带PTC细胞的Ncr-nu/nu鼠
  • Dosages: 20-25 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 96 mg/mL (199.09 mM)
Water Insoluble
Ethanol '40 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 482.19
化学式

C16H14F3IN2O4

CAS号 391210-10-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • 回答:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

相关MEK产品

Tags: 购买Mirdametinib (PD0325901) | Mirdametinib (PD0325901)供应商 | 采购Mirdametinib (PD0325901) | Mirdametinib (PD0325901)价格 | Mirdametinib (PD0325901)生产 | 订购Mirdametinib (PD0325901) | Mirdametinib (PD0325901)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID